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Background. The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has been increasing in the last five
decades, but there is no large-scale data regarding these tumours in Portugal. We conducted a cross-sectional, multicentric study in
main Portuguese centers to evaluate the clinical, pathological, and therapeutic profile of GEP-NENs. Methods. From November,
2012, to July, 2014, data from 293 patients diagnosed with GEP-NENs from 15 centers in Portugal was collected and registered
in an online electronic platform. Results. Median age at diagnosis was 56.5 (range: 15-87) years with a preponderance of females
(54.6%). The most frequent primary sites were the pancreas (31.1%), jejunum-ileum (24.2%), stomach (13.7%), and rectum
(8.5%). Data regarding hormonal status was not available in most patients (82.3%). Stratified by the tumour grade (WHO 2010
classification), we observed 64.0% of NET G1, 24.7% of NET G2, and 11.3% of NEC. Poorly differentiated tumours occurred
mainly in older patients (p = 0 017), were larger (p < 0 001), and presented more vascular (p = 0 004) and lymphatic (p = 0 001)
invasion. At the time of diagnosis, 44.4% of GEP-NENs presented metastatic disease. Surgery (79.6%) and somatostatin
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analogues (30.7%) were the most frequently used therapies of GEP-NENs with reported grading. Conclusion. In general, Portuguese
patients with GEP-NENs presented similar characteristics to other populations described in the literature. This cross-sectional
study represents the first step to establish a national database of GEP-NENs that may aid in understanding the clinical and
epidemiological features of these tumours in Portugal.
1. Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous
group of rare malignancies originating from endodermal
cells with secretory capacity within the neuroendocrine sys-
tem. Gastroenteropancreatic- (GEP-) NENs represent a sub-
type of these tumours, located either in the pancreas or in the
gastrointestinal tract [1]. Although the incidence is low, it has
been increasing significantly in the recent years; the age-
adjusted incidence rate increased 6.4-fold from 1973 (1.09
per 100,000 persons) to 2012 (6.98 per 100,000 persons)
[2]. Due to the long survival rate of patients with these
tumours, the estimated 20-year limited-duration prevalence
of NENs in the USA on January 1, 2014, was 171,321 [2].
The long survival reflects, besides the intrinsic biologic char-
acteristics of neuroendocrine cells, the advances in diagnostic
techniques and the awareness among clinicians [3].
NENs can be classified into functional and nonfunctional
tumours according to thepresenceor absenceof clinical symp-
toms associated with hormone overproduction [4]. Nonspe-
cific symptoms are evident in the majority of nonfunctional
cases resulting in a delay in diagnosis. NENs have been a sub-
ject of long debate regarding nomenclature, grading, and clas-
sification. The 2010 World Health Organization (WHO)
classification,developed togetherwith theEuropeanNeuroen-
docrine Tumour Society (ENETS), presented a significant
progress by using two separate and complementary classifica-
tion tools: histologic grading and site-specific staging system,
classifyingNENsaccording to theproliferation index (fraction
of Ki-67 staining or number of mitotic counts) into grade 1
(G1), grade 2 (G2), and neuroendocrine carcinoma (NEC)
[5]. In 2017, this WHO classification was updated, and the
NENs are now divided into 3 main categories: mixed
neuroendocrine-nonneuroendocrine neoplasms (MiNEN),
NEN G1/G2/G3 (well-differentiated NEN), and NEC G3
(poorly differentiated NEN, large or small cell subtypes). The
main differences in comparison with the 2010 classification
are theKi-67 index ofNENG1 tumours thatwas altered to less
than 3% (instead of ≤2%) and an additional NENG3 subcate-
gory that was added to the well-differentiated NENs, with a
labelling index of more than 20% for Ki-67 or more than 20
mitotic counts per 10HPF.NECG3 (poorly differentiated car-
cinomas) also require a Ki-67 proliferative index higher than
20%, as well as more than 20 mitotic counts per 10 HPF [6].
The aims of the available treatment options are to pro-
mote symptom relief, improve life quality, and ideally, a
disease-free setting in patients which is largely dependent
on primary tumour size and localization. These therapies
vary from conservative procedures to pharmacologic and
surgical management, and patterns of care differ between
hospitals and countries depending on medical teams, experi-
ence and available resources.
Due to paucity of data on GEP-NENs in Portugal, the
Neuroendocrine Tumours Study Group (GE-TNE) of the
Portuguese Society of Endocrinology, Diabetes and Metabo-
lism (SPEDM) sought to perform an observational study to
present an outline of GEP-NEN patients followed up at the
main Portuguese hospitals regarding their sociodemographic
and clinical profiles (spectrum of symptoms at presentation,
methods used in the diagnosis, and treatment modalities
applied). These data will contribute towards the effort of
developing a National Registry for effective monitoring of
NENs and emphasize its importance as well as the need for
multidisciplinary involvement for a comprehensive manage-
ment of GEP-NENs in Portugal.
2. Materials and Methods
We designed a cross-sectional multicenter evaluation of
patients diagnosed with GEP-NENs in 15 Portuguese centers
that agreed to participate in the study. Inclusion criteria were
patients with more than 18 years of age, a confirmed diagno-
sis of GEP-NEN based on histopathological, cytological,
and/or biochemical/nuclear imaging findings, and a signed
informed consent for study inclusion. Patients were consecu-
tively enrolled in the study as they attended their medical
appointment during a continuous 18-month period of the
study. At the time of enrollment, data were collected directly
from patients and from clinical files and submitted to an elec-
tronic platform. Variables included age, gender, GEP-NEN
subtype, site of the primary tumour, WHO 2010 grading
classification, tumour stage at diagnosis, symptoms at pre-
sentation, diagnostic procedures, hormonal and biochemical
evaluations, treatment procedures, and duration of follow-
up. Carcinoid syndrome was defined as values of 5-
hydroxyindoleacetic acid (5-HIAA) equal or greater than
twice the upper limit of the normal range plus flushing
and/or diarrhea. Insulinoma diagnosis was based on hypo-
glycemic symptoms, Whipple triad, and/or a positive 72-
hour prolonged fasting test. Gastrinoma diagnosis was based
on clinical picture and gastrin levels greater than ten times
the upper limit of the normal range, after excluding chronic
atrophic gastritis and PPI (proton pump inhibitors) use. Ima-
giological procedures were evaluated according to primary
tumour location. The tumour stage was classified as localized
(confined to the organ of origin), regional (invasion of the
surrounding organs or tissues or regional lymph nodes), or
distant (spread to distant organs).
Ethical principles concerning ESP-GPP (Expanded Scope
of Practice-Good Pharmacy Practicing), Helsinki Declara-
tion, and National Legislation requirements were fulfilled.
Statistical analysis was performed with SPSS® statistics
(software version 15.0). Categorical and continuous variables
were summarized using descriptive statistics (frequencies for
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categorical variables and mean/standard deviation or media-
n/interquartile range for continuous variables, as appropri-
ate). Proportions were compared by the Chi-squared test or
Fisher’s exact test, as appropriate. Means were compared
using the t-test or ANOVA.
3. Results
3.1. General Characteristics of the Population. A total of 314
cases were collected, whereas only 293 patients were included
in the present study; the remaining 21 patients were excluded
as they did not meet the inclusion criteria, such as lack of
clinical information or the absence of informed consent.
Data are summarized in Table 1.
Briefly, the cohort presented a 1 : 1.2 male to female ratio
(133 males and 160 females), with a median age at diagnosis
of 56.5 years (range: 15–87). The primary tumour site was
predominantly the pancreas (31.1%), followed by the
jejunum-ileum (24.2%), the stomach (13.7%), and the rec-
tum (8.5%).
Clinically/hormonal functional syndrome was identified
in 16.5% of patients: 17 presented criteria for carcinoid syn-
drome, 11 for insulinoma, and 4 for gastrinoma. No other
hypersecreting tumours were detected in this series.
The majority of cases were diagnosed by histopathology
or cytopathology, 86.7% and 5.8%, respectively, and less fre-
quently (1.7%) by biochemistry, namely, in insulinomas.
According to the WHO 2010 classification, cases where
graded as NET G1 (n = 158, 64.0%), NET G2 (n = 61,
24.7%), and NEC (n = 28, 11.3%); in 46 cases, data was not
available. Information regarding extension of the disease
was available in 214 cases and revealed localized disease in
35.5% of cases (including gastric, duodenum, and colorectal
polyps) and distant disease in 44.4%. Regional spread was
present in 20.1% of the cases.
The sociodemographic and clinical features of GEP-NEN
patients, according to the tumour grade, are summarized in
Table 2. NET G1 were more frequently detected in females
(72.1%), whereas NET G2 and NEC were more common in
males, 31.4% and 13.6%, respectively, (p = 0 020). There
was a significant association between the WHO 2010 tumour
grading and age at diagnosis (p = 0 017), with NEC being
diagnosed at a median age of 62.5 years (range: 39–84) vs.
56.5 years (range: 32–80) for NET G2 and 54.7 years (range:
15–85) for NET G1. Patients with well-differentiated NENs
presented a significantly higher mean body mass index
(BMI) (p = 0 015) in comparison with NEC patients. There
was a significant association of smoking and alcohol con-
sumption with NET G2 (p = 0 007) and NEC (p = 0 037).
NEC patients had less comorbidities than patients of the
other two groups of NENs (57.6% vs. 71.4% in NET G1 and
75.8% in NET G2); these results were not statistically signif-
icant. There was a significant association between WHO
2010 tumour grading groups and primary tumour size at
diagnosis, higher in NEC (p < 0 001). Vascular and lym-
phatic invasions were significantly more frequent in NEC
(p = 0 004 and p = 0 001, respectively), whereas perineural
invasion presented the same trend without statistical signifi-
cance (p = 0 064).
Table 1: Patient general characteristics.
Gender ( n = 293)
Male, n (%) 133 (45.4)
Female, n (%) 160 (54.6)
Age (years,n = 293)
Median (range) 59.9 (22-89)
Age at diagnosis (years,n = 291)
Median (range) 56.5 (15‡-87)
Race ( n = 293)
Caucasian, n (%) 285 (97.3)
African, n (%) 1 (0.3)
Other or not specified, n (%) 7 (2.4)
Type of diagnosis (n = 293)
Histopathological, n (%) 254 (86.7)
Cytological, n (%) 17 (5.8)
Biochemical, n (%) 5 (1.7)
Other or not specified, n (%) 17 (5.8)
Primary tumour by localization (n = 293)
Pancreas, n (%) 91 (31.1)
Head, n (%) 28 (30.7)
Body, n (%) 29 (31.9)
Tail, n (%) 32 (35.2)
Not specified, n (%) 2 (2.2)
Jejunum-ileum, n (%) 71 (24.2)
Stomach, n (%) 40 (13.7)
Type 1, n (%) 23 (57.5)
Type 2, n (%) 9 (22.5)
Type 3, n (%) 7 (17.5)
Not specified, n (%) 1 (2.5)
Rectum, n (%) 25 (8.5)
Duodenum, n (%) 20 (6.8)
Appendix, n (%) 20 (6.8)
Colon, n (%) 16 (5.5)
Oesophagus, n (%) 3 (1.0)
Unknown primary tumour 7 (2.4)
Tumour group by secretion
Carcinoid syndrome∗, n positive/total
studied∗∗ (%)
17/115 (14.8)
Gastrinoma$, n positive/total studied$$ (%) 4/55 (7.3)
Insulinoma&, n positive/total studied&& (%) 11/24 (45.8)
Tumour group by grade (n = 247); WHO, 2010
NET G1, n (%) 158 (64.0)
NET G2, n (%) 61 (24.7)
NEC, n (%) 28 (11.3)
Tumour group by stage (n = 214); TNM (ENETS)
Localized, n (%) 76 (35.5)
Locoregional, n (%) 43 (20.1)
Disseminated, n (%) 95 (44.4)
‡Patient was 15 y old at diagnosis, currently 22 y old at the time of the study;
∗carcinoid syndrome criteria: 5 −HIAA > 2 times the normal value and
flushing and/or diarrhea; ∗∗cases with 5-HIAA quantification; $gastrinoma
criteria: gastrin ≥ 10 times the normal value and exclusion of types I and II
gastric tumours; $$cases with gastrin quantification; &insulinoma criteria:
hypoglycemic symptoms, Whipple triad, and/or positive 72-hour
prolonged fasting test; $$cases with insulin quantification.
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Multiple endocrine neoplasia type 1 (MEN-1) syndrome
was diagnosed in 4 patients; two patients had pancreatic
tumours and two patients with gastric tumours. All patients
with MEN-1 syndrome had primary hyperparathyroidism,
and two patients had a pituitary adenoma and an adrenal
adenoma, respectively.
Table 2: Sociodemographic and clinical features of patients and tumour characteristics according to WHO tumour classification (grading).
(a)
NET G1 NET G2 NEC
Total no. of patients (n = 247) 158 (64.0) 61 (24.7) 28 (11.3)
(b)
NET G1 NET G2 NEC p
Gender (n = 247)
Male (n = 118), n (%) 65 (55.1) 37 (31.4) 16 (13.6)
0.020
Female (n = 129), n (%) 93 (72.1) 24 (18.6) 12 (9.3)
Age (n = 247), years (mean (SD)) 58.3 (12.8) 59.8 (12.7) 63.0 (12.9) 0.176
Age at diagnosis (n = 246), years (median range) 54.7 (15-85) 56.5 (32-80) 62.5 (39-84) 0.017
Weight (n = 190), kg (mean (SD)) 71.8 (13.2) 76.9 (17.5) 68.7 (10.8) 0.049
BMI (n = 149), kg·m-2 (mean (SD)) 27.0 (4.6) 28.6 (5.7) 24.6 (3.1) 0.015
Comorbidities (n = 231), n (%) 105 out of 147 (71.4) 44 out of 58 (75.8) 15 out of 26 (57.6) 0.233
Arterial hypertension (n = 235), n (%) 29 out of 150 (19.3) 5 out of 58 (8.6) 3 out of 27 (11.1) 0.139
Diabetes mellitus (n = 234), n (%) 17 out of 149 (11.4) 4 out of 58 (6.9) 1 out of 27 (3.7) 0.417
Dyslipidaemia (n = 239), n (%) 15 out of 154 (9.7) 3 out of 58 (5.1) 3 out of 27 (11.1) 0.508
Cardiovascular disease (n = 235), n (%) 8 out of 150 (5.3) 2 out of 58 (3.4) 1 out of 27 (3.7) 0.897
Family history of nonendocrine neoplasm (n = 167), n (%) 51 out of 105 (48.6) 22 out of 42 (52.4) 6 out of 20 (30.0) 0.254
Smoking (n = 173), n (%) 3 out of 110 (2.7) 4 out of 42 (9.5) 3 out of 21 (14.3) 0.007
Alcohol consumption (n = 163), n (%) 38 out of 106 (35.8) 22 out of 37 (59.5) 10 out of 20 (50.0) 0.037
Tumour dimension (n = 213), mm (mean (SD)) 21.3 (19.9) 32.7 (23.5) 51.7 (34.9) <0.001
Vascular invasion (n = 162), n (%) 34 out of 106 (32.1) 24 out of 41 (58.5) 9 out of 15 (60.0) 0.004
Lymphatic invasion (n = 155), n (%) 39 out of 103 (37.8) 25 out of 36 (69.4) 11 out of 16 (68.7) 0.001
Perineural invasion (n = 119), n (%) 26 out of 84 (31.0) 9 out of 25 (36.0) 7 out of 10 (70.0) 0.064
(c)
NET G1 NET G2
Hormonal status
Functioning (n = 32)a 17 out of 32 (53.1) 6 out of 32 (18.6)
Carcinoid (n = 17)b 8 out of 17 (47.0) 5 out of 17 (29.4)
Gastrinoma (n = 4)c 2 out of 4 (50.0) 1 out of 4 (25.0)
Insulinoma (n = 11)d 7 out of 11 (63.6) 0
Nonfunctioning, (n = 20)e 12 out of 20 (60.0) 5 out of 20 (25.0)
(d)
NET G1 NET G2 NEC p
MEN-1 syndrome (n = 213)§ 2 out of 137 (1.5) 2 out of 51 (3.9) 0 out of 25 (0.0) 0.575
Stage (n = 186)
Localized, n (%) 51 out of 114 (44.7) 11 out of 48 (22.9) 4 out of 24 (16.7)
0.001Locoregional, n (%) 26 out of 114 (22.8) 10 out of 48 (20.8) 2 out of 24 (8.3)
Disseminated, n (%) 37 out of 114 (32.5) 27 out of 48 (56.3) 18 out of 24 (75.0)
Cases missingWHO tumour classification grading: an = 9, bn = 4, cn = 1, dn = 4, and en = 3. §Cases reported as not presentingMEN-1 syndrome clinical features
(no genetic testing was performed for unsuspicious cases).
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3.2. Biochemical Tests. Biochemical data analysis concerning
hormonal hypersecretion was informative in 32 patients
(10.9%). Chromogranin A (CgA) equal or greater than twice
the normal value was detected in 86 (51.2%) of the 165
patients evaluated (Table 3). Concerning specific markers,
urinary 5-HIAA was evaluated in 115 patients and was
positive in 47 (40.9%); of these, 17 patients presented car-
cinoid syndrome criteria. Insulinoma was identified in 11
patients (3.6%) either by Whipple’s triad criteria and/or
positive prolonged fasting test. Four sporadic gastrinomas
were identified (Table 1).
3.3. Imaging Studies. The imaging modalities used as a
diagnostic procedure—either for primary tumours or for
metastases—are presented in Table 4. A computerized
tomography (CT) scan was performed in 233 (79.5%) of
the 293 patients and identified primary and/or metastatic
tumour location in 79.5% of the evaluated cases. Octreos-
can® was performed in 121 (41.3%) of the 293 patients
and was informative in 63.6% of the evaluated cases. A
68Ga-positron emission tomography- (PET-) SSTR scan
was used in 99 (33.8%) of the 293 patients and was infor-
mative in 75.8% of the evaluated cases. 111In-pentetreotide
(111In-octreoscan®) (Octreoscan®) and 68Ga-PET-SSTR
scan were mainly used in NET G1 and NET G2 patients,
89.8% and 93.1%, respectively. Fluorodeoxyglucose- (FDG-)
PET was evaluated in 36 (12.3%) of 293 patients. Upper
gastrointestinal endoscopy presented the highest efficiency
in localizing oesophageal (3 out of 3, 100%), gastric (27 out
of 30, 90%), and duodenal (17 out of 19, 89.5%) tumours.
Echoendoscopy was valuable in the detection of duodenal
(6 out of 6, 100%), pancreatic (25 out of 28, 89.3%), and
gastric (7 out of 13, 53.8%) tumours. A colonoscopy was
the main diagnostic procedure in colonic NEN detection
(12 out of 12, 100%), as well as in rectal NENs (21/22,
95.5%). For midgut tumours, magnetic resonance imaging
(MRI), CT, and video capsule were the mostly used imag-
ing procedures; PET for somatostatin receptors (SSTR),
68Ga-PET-SSTR, demonstrated to be the most sensitive
(94.1%) imaging tool.
3.4. Extension of the Disease. Extension of the disease was
evaluated in 186 patients (Figure 1 and Table 2). Localized
disease was more frequent in NET G1 (44.7%). Regional dis-
ease was detected in 20.1% of the patients: 22.8% with NET
G1, 20.8% with NET G2, and 8.3% with NEC. Metastases
were present in 32.5% of patients with NET G1, in 56.3%
with NET G2, and in 75.0% with NEC. Among cases with
distant metastases at presentation (n = 82), 30.5% presented
liver metastases. Bone metastases were detected in one
patient with a NET G2 and two patients with NEC. Only
one patient with NEC had lung metastases. Other sites of dis-
tant metastases included the peritoneum (five patients: one
NET G1, one NET G2, and three NEC), adrenal glands
(one patient with NEC), ovary (one patient with NET G1),
and inferior vena cava (one patient with NET G1).
3.5. Treatment Procedures. Endoscopic removal of the
tumours was possible in 40 patients with localized gastric,
duodenal, and colorectal NENs. According to the WHO
2010 classification, either curative or cytoreductive surgery
was performed in 125 out of 155 cases (80.6%) of NET G1,
48 out of 60 cases (80.0%) of NET G2, and 18 out of 25 cases
(72.0%) of NEC (Table 5); overall, 191 of 240 patients
(79.6%) were treated with surgery. Concerning patients with
disseminated disease, 22 patients (18.2%) with NET G1, 9
patients (20.5%) with NET G2, and 8 patients (44.4%) with
NEC were submitted to debulking surgery, mainly liver
metastasectomy.
Although 95 patients presented liver metastases at
diagnosis, locoregional ablative therapy, such as transarter-
ial embolization (TAE), transarterial chemoembolization
(TACE), radioembolization, or radiofrequency (RF)/ther-
moablation (TA), was only performed in 14 patients with
well-differentiated NETs; 70.0% of the cases submitted to
TAE and 75.0% submitted to RF/TA were NET G1. Only
four patients were submitted to radioembolization, being
three NET G1 and one NET G2.
Systemic therapy included somatostatin analogues
(SSAs), interferon-α2b, target therapies with tyrosine kinase
inhibitors and mTOR inhibitors, peptide receptor radiother-
apy (PRRT), and chemotherapy (Table 5, Figure 2).
SSAs were mostly used in well-differentiated NETs
(p < 0 001), comprising 20.4% of NET G1, 59.3% of NET
G2, and 32.0% of NEC. Only 4 patients received combined
treatment with SSAs and interferon-α2b. Target therapies
as sunitinib and everolimus were used in seven (3.0%)
patients: two with NET G1, two with NET G2, and three with
NEC. Peptide receptor radiotherapy (PRRT) was used in nine
(3.9%) of the patients, mainly well-differentiated NETs
(33.3% NET G1 and 66.7% NET G2). Chemotherapy treat-
ment was performed in 20 patients, mostly in NEC of the
colon and the pancreas (11 patients; p < 0 001).
4. Discussion
GEP-NENs have been historically considered a rare and
heterogeneous group of neoplasms. They comprise approx-
imately 0.5% of all human cancers and 2% of gastrointesti-
nal tumours [1]. New data from SEER 18 [2] reported a
6.5-fold increase in the annual incidence from 1973 to
2012 in NENs [2], reinforcing the need for research in this
field. GEP-NENs often exhibit relatively indolent clinical
Table 3: Biochemical tests.
Biochemical tests Positive results, n (%)
Chromogranin A (n = 168) 86 (51.2)
5-HIAA (n = 115) 47 (40.9)
Insulin (n = 25) 11 (44.0)
Gastrin (n = 55) 25 (45.5)
Glucagon (n = 8) 0
VIP (n = 9) 0
ACTH (n = 17) 0
GH (n = 12) 0
VIP: vasoactive intestinal peptide; ACTH: adrenal corticotrophin; GH:
growth hormone.
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courses and a delay in the diagnosis and tend to present
metastases at the time of diagnosis, preserving the potential
for lethal progression.
The present study was designed to characterize the over-
all scenario of GEP-NENs in Portugal, namely, the incidence
and epidemiology of these tumours, sociodemographic and
clinical profiles of the patients, and the patterns of care in a
multicenter audit. Our results provide a comprehensive and
relevant information on a group of neoplasm still poorly
characterized, particularly, in Southern Europe. Published
data from GEP-NEN in European countries is available in a
French registration study [7], in a Spanish study of the Neu-
roendocrine Tumours Study Group Registry of Spain
(RGETNE) [8], in an Italian epidemiological study [9], in a
prospective Greek registry [10], and in the United Kingdom
and Northern European countries [11–13]. Worldwide, the
most characterized cohorts are from the United States of
America (USA) [2, 14], and there is data available from Asian
countries, such as China [15] and Japan [16].
Overall, our findings are in accordance with reports of
NENs from other countries and corroborate that they are a
heterogeneous group of tumours with a wide range of clinical
presentation. We observed a similar gender ratio with a
slight preponderance for females, as observed in a USA
series [13, 14], Canadian series [17], and Italian study [9].
In our series, the pancreas was the most frequent primary
tumour site, followed by the jejunum-ileum and the stomach.
These findings are in agreement with data from Southern
European countries, as the Italian and Greek cohorts [9, 10]
as well as in China [18], but in contrast with other pub-
lished studies [2, 7, 8, 17], where the gastrointestinal tract
was reported as the most frequent primary site. These
inconsistencies may be due to a referral bias and may
suggest geographic and ethnic variation in the carcino-
genesis of GEP-NENs. A recent publication stresses the
differences in geographic and ethnic distribution, other
than NEN fortuitous location and identification related
to the current accuracy of the diagnostic methods [19],
and points to the possibility of involved environmental
risk factors. Prospective and larger studies will be useful
to further clarify these findings.
The present study provides a comprehensive report on
diagnostic and therapeutic procedures used in the current
clinical practice in Portugal. Like the Spanish results reported
by the RGETNE, in Portugal, there is a limited overall use of
biochemical tests at diagnosis, namely, the general marker
serum chromogranin A or urinary 5-HIAA quantification
for midgut tumours.
In our cohort, as in another series [8], the most frequent
functioning tumour was NEN with carcinoid syndrome,
followed by insulinoma and apparently sporadic gastrinoma.
No glucagonoma, VIPoma, somatostatinoma, or other rare
syndromes were identified. It should also be taken into con-
sideration that in 71.7% of the cases, the hormonal secretion
by the tumour was not evaluated. This seems to reflect a low
referral rate of patients to specialized centers, low participa-
tion of endocrinologists in the oncology team, and/or a lim-
ited laboratory support in some of the institutions that
participated in this study. Our results highlight the ongoing
demand for an adequate management of diagnostic, treat-
ment, and follow-up work-out for patients with GEP-
NENs. Most of the international epidemiological studies
report data about localization, histological classification,
and staging of GEP-NENs, but information about their
hormonal secretion is sparse. Biochemical evaluation is
important, not only for diagnostic purposes but also for
therapeutic decision and monitoring of treatment responses,
and an adequate assessment of tumour secretion is strongly
encouraged. Genetic testing is also important when clinically
indicated, as it allows for (1) a personalized life-long screen-
ing for prototypic tumours and their timely treatment, (2) the
identification of affected family members that may benefit
from this screening, and (3) appropriate genetic counseling.
In our series, the majority of the cases lacked genetic evalua-
tion for clinical suspicion of hereditary syndromes.
Histological classification of NENs is evolving as the
WHO revised the nomenclature and classification of GEP-
NENs in 2010 [5] and updated it in 2017 [6]. Histopatholog-
ical characterization with immunohistochemistry markers
such as chromogranin and synaptophysin is essential to
make the diagnosis. The mitotic index and/or immunohisto-
chemistry for Ki-67 labelling index is mandatory to generate
the tumour grading [4]; these are minimum requirements for
an accurate pathological classification. At the time of the
inclusion of the patients in the present study, the histological
classification was performed according to the 2010WHO cri-
teria, the up-to-date guidelines used for this study. Overall, in
this study, the frequency of NET G1, NET G2, and NEC fits
with other reports.
Tumour metastases at diagnosis represent an important
prognostic marker [2]. In this series, distant metastases were
detected in 44.4% of patient (NET G1: 32.5%; NET G2:
56.3%; and NEC: 75.0). This is consistent with other studies,
as the Spanish and Italian studies [8, 9], where distant metas-
tases were observed in 44% and 42% of patients, respectively,
and contrasts with a lower rate of distant metastases at diag-
nosis in the Greek [10], Chinese [15], and Canadian [17]
studies (25.0%, 6.0%, and 20.8%, respectively), as well as the
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Figure 1: Extension of disease according to WHO 2010
classification.
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SEER Registry (21.0%) [14]. An explanation for these differ-
ences may be due to the inclusion of cases from oncological
institutions, where the proportion of metastatic disease is
considerably higher. In this study, the oncological institu-
tions, from Lisbon and Porto, contributed with 46% of the
patients included.
Endoscopic therapy is the mainstay for types 1 and 2
gastric endocrine tumours and for localized duodenal
and colorectal NENs. In this cohort, endoscopic therapy
was performed mainly in those cases.
Surgery remains the treatment of choice for GEP-NENs,
with curative intent whenever feasible. If the tumour is unre-
sectable, several approaches are available to induce tumour
debulking as a manner to control life-threatening symptoms
due to hormone secretion and to increase patient survival
and quality of life [20, 21]. In experienced centers, ablative
therapies are a good option to treat liver metastatic disease
[22]. Our results show that either primary or cytoreductive
surgery was performed in the majority of the hospitals
included and mainly in well-differentiated NENs. Ablative
therapies were used in less than 5% of the patients proba-
bly due to the fact that few centers have this treatment
available. This finding indicates the need of a referral of
the patients to centers where they can benefit from these
therapeutic options.
Currently, the standard of care for systemic treatment in
advanced NET treatment is SSA, which proved to be effective
in controlling excessive hormonal secretion [23, 24] and
allowing long-term improvement in secretory symptoms in
30–70% of patients. Recent studies report an additional anti-
proliferative role of SSA in nonfunctioning midgut [25], pan-
creatic, and lung NENs [26], which reflected in the significant
progression-free survival in the treated patients when
compared with placebo. Other therapeutic options include
biologic agents interfering with specific molecules of cell sig-
naling pathways, e.g., the mammalian target of rapamycin
(mTOR) and vascular endothelial growth factor (VEGF),
with everolimus and sunitinib, respectively, both approved
for pancreatic NENs [27, 28]. Everolimus was also approved
for the treatment of advanced nonfunctioning lung and gas-
trointestinal NENs [29]. Studies using oral chemotherapy
with temozolomide and capecitabine are demonstrating
promising results in well-differentiated pancreatic NENs
[30]. However, classic cytotoxic drugs still continue to be
the first-line therapy for poorly differentiated GEP-NENS
and are effective (up to 60% response rates) in well-
Table 5: Treatments administered to patients with GEP-NETs.
(a)
Gastric, n (%) Duodenum, n (%) Rectum, n (%)
Endoscopic therapy (n = 40) 21 (52.5) 4 (10.0) 15 (37.5)
(b)
NET G1 NET G2 NEC p
Surgical therapy (n = 240)$ 125 out of 155 (80.6) 48 out of 60 (80.0) 18 out of 25 (72.0) 0.607
Surgery of metastases (n = 183)$ 22 out of 121 (18.2) 9 out of 44 (20.5) 8 out of 18 (44.4) 0.055
Liver ablative therapy
TAE (n = 199)$ 7 out of 131 (5.3) 3 out of 49 (6.1) 0 out of 19 (0.0) 0.781
RFA (n = 101)$ 3 out of 61 (4.9) 1 out of 27 (3.7) 0 out of 13 (0.0) >0.999
Systemic therapies
Somatostatin analogues (n = 231)$ 31 out of 152 (20.4) 32 out of 54 (59.3) 8 out of 25 (32.0) <0.001
Interferon (n = 231)$+SSAs 3 out of 152 (2.0) 1 out of 55 (1.8) 0 out of 24 (0.0) >0.999
Target therapies∗ (n = 231)$ 2 out of 153 (1.3) 2 out of 53 (3.8) 3 out of 25 (12.0) 0.020
PRRNT∗∗ (n = 230)$ 3 out of 150 (2.0) 6 out of 55 (10.9) 0 out of 25 (0.0) 0.021
Chemotherapy (n = 244)$ 3 out of 157 (1.9) 6 out of 60 (10.0) 11 out of 27 (40.7) <0.001
$Number of cases with information. TAE = transhepatic arterial embolization; RFA = radiofrequency ablation; PRRNT: peptide receptor radionuclide therapy.
∗Sunitinib; ∗∗177Lu-THERA.
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differentiated pancreatic NETs; however, early relapses often
occur [31]. Concerning the therapeutic options in the present
study, endoscopic therapies, either curative or cytoreductive
surgery, and SSA treatment were the preferred options for
the majority of patients. Somatostatin analogues (SSAs) were
the most frequently used drugs in our study. Locoregional
ablative therapy, PRRT, and target therapies were rarely used.
Remarkably, PRRNT was more frequently chosen than target
therapies. This fact was remarkable, as in the Portuguese
National Health System, only one center offered this thera-
peutic modality at the time of the present study. As in other
series and according to the guidelines, chemotherapy was
the treatment of choice in NEC and was also an option in
well-differentiated nonpancreatic NETs, which may reflect
the inclusion of older cases and/or the absence of a referral
to specialized centers.
The results obtained in this study represent the first
comprehensive registry of GEP-NENs in Portugal per-
formed by the Neuroendocrine Study Group of the Portu-
guese Society of Endocrinology, Diabetes and Metabolism.
These provide a valuable insight into the epidemiology,
current clinical practice, and therapy strategies of this het-
erogeneous disease and will set the ground for the devel-
opment of a National Registry of NENs. These reinforce
the need for a national clinical framework for GEP-NENs,
in order to ensure a systematic surveillance of the disease
and ultimately improve the diagnosis, clinical manage-
ment, and outcome of NEN patients.
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